You are viewing an incomplete version of our website. Please click to reload the website as full version.

Inhibin alpha antibody (Inhibin, alpha)

Details for Product anti-INHA Antibody No. ABIN1107756, Supplier: Log in to see
Antigen
  • AW555078
  • INHA
  • MGC108500
  • si:dkey-91f15.2
Reactivity
Human, Mouse (Murine)
193
72
49
16
12
4
3
2
1
Host
Mouse
160
67
11
Clonality (Clone)
Monoclonal ()
Conjugate
This Inhibin alpha antibody is un-conjugated
20
18
8
4
3
3
3
3
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
Application
Enzyme Immunoassay (EIA), Immunofluorescence (IF), Western Blotting (WB)
131
114
76
60
45
38
23
14
8
5
4
4
3
3
2
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Clone 4-00E-002
Isotype IgG1
Specificity Recognizes Inhibin alpha / INHA
Cross-Reactivity (Details) Species reactivity (tested):Human, Mouse.
Purification Ascites
Alternative Name Inhibin alpha / INHA (INHA Antibody Abstract)
Background Inhibins are peptide hormones produced by the granulosa cells in female follicles and by Sertoli cells in the male seminiferous tubules. They are selectively expressed by cells of sex cord stromal derivation, and inhibit the secretion of follitropin by the pituitary gland. Inhibins are also involved in regulating diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins, as inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibin has 2 subunits (alpha and beta) that are coded by separate genes. The alpha subunit determines whether inhibin or activin will be produced. The alpha subunit remains constant, such that the various types of inhibin are defined by the beta subunit (a,b,c,d). Inhibin A is a dimer of alpha and beta A. Inhibin B is a dimer of alpha and beta B. Proteolytic processing yields a number of inhibin alpha bioactive forms: the 20/23 kDa forms consist solely of the mature alpha chain, the 26/29 kDa forms consist of the most N terminal propeptide linked through a disulfide bond to the mature alpha chain, and the 50/53 kDa forms encompass the entire proprotein. Each type can be furthermore either mono or diglycosylated, causing the mass difference.
Molecular Weight 40 kDa
Gene ID 3623
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Liquid
Supplier Images
Western Blotting (WB) image for anti-Inhibin alpha antibody (Inhibin, alpha) (ABIN1107756) anti-Inhibin, alpha (INHA) antibody
Immunofluorescence (IF) image for anti-Inhibin alpha antibody (Inhibin, alpha) (ABIN1107756) anti-Inhibin, alpha (INHA) antibody (Image 2)
Background publications Makovitzky, Radtke, Shabani, Friese, Gerber, Mylonas: "Invasive hydatidiform mole: immunohistochemical labelling of inhibin/activin subunits, Ki67, p53 and glycodelin A in a rare case." in: Acta histochemica, Vol. 111, Issue 4, pp. 360-5, 2009 (PubMed).

Corre, Schuettler, Bione, Marozzi, Persani, Rossetti, Torricelli, Giotti, Vogt, Toniolo: "A large-scale association study to assess the impact of known variants of the human INHA gene on premature ovarian failure." in: Human reproduction (Oxford, England), Vol. 24, Issue 8, pp. 2023-8, 2009 (PubMed).

Palmieri, Wilson, Iversen, Clyde, Calingaert, Moorman, Poole, Anderson, Anderson, Anton-Culver, Beesley, Hogdall, Brewster, Carney, Chen, Chenevix-Trench, Chang-Claude, Cunningham, Dicioccio, Doherty et al.: "Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. ..." in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 17, Issue 12, pp. 3567-72, 2008 (PubMed).